Silver Book Fact

The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).

Javitt, Jonathan C., and Lloyd Paul Aiello. Cost-Effectiveness of Detecting and Treating Diabetic Retinopathy. Annals of Internal Medicine. 1996; 124(1): 164-9. http://www.annals.org/cgi/content/abstract/124/1_Part_2/164

Reference

Title
Cost-Effectiveness of Detecting and Treating Diabetic Retinopathy
Publication
Annals of Internal Medicine
Publication Date
1996
Authors
Javitt, Jonathan C., and Lloyd Paul Aiello
Volume & Issue
Volume 124, Issue 1
Pages
164-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Mobile Exam for DR
    Use of a mobile examination for DR screening in Finland decreased visual impairment by 86% in the covered area.  
  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…  
  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)  
  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.